Insmed TPIP Data At PVRI 2026 Tests Pulmonary Arterial Hypertension Ambitions [Yahoo! Finance]
Insmed, Inc. (INSM)
Last insmed, inc. earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
Insmed (NasdaqGS:INSM) plans to present new clinical and preclinical research on treprostinil palmitil inhalation powder (TPIP) at PVRI 2026. The company will share Phase 3 trial design and Phase 2b topline results in pulmonary arterial hypertension. These presentations are scheduled for the Pulmonary Vascular Research Institute annual meeting in 2026. Insmed focuses on therapies for serious and rare diseases, and TPIP is part of its efforts in pulmonary arterial hypertension. For investors, the PVRI 2026 presentations provide an updated view of how the company is progressing its pipeline, at a time when pulmonary care and targeted respiratory treatments remain an active area of drug development. As you assess NasdaqGS:INSM, the upcoming TPIP data may help you better understand the company's clinical priorities, the scope of its pulmonary program, and how it is positioning itself within rare disease treatment. The details from PVRI 2026 may inform how you think about risk, ti
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed, Inc. news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed (NASDAQ:INSM) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.MarketBeat
- Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 CongressPR Newswire
- Insmed (NASDAQ:INSM) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.MarketBeat
- Insmed (NASDAQ:INSM) was upgraded by analysts at Roth Mkm to a "strong-buy" rating.MarketBeat
- Insmed (NASDAQ:INSM) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
INSM
Earnings
- 10/30/25 - Miss
INSM
Sec Filings
- 1/22/26 - Form 4
- 1/21/26 - Form SCHEDULE
- 1/20/26 - Form 144
- INSM's page on the SEC website